Venture Map · Round
ADmit Therapeutics — Series A · €5.4M
Announced 2023-10-06 · L'Hospitalet de Llobregat · Biotech / Diagnostics
The IDIBELL spin-off, which uses mitochondrial DNA methylation patterns in blood to predict which mild-cognitive-impairment patients will progress to Alzheimer's, raised a €5.4M equity round led by Clave Capital through its Clave Innohealth fund. Proceeds go towards CE marking and FDA approval for its MAP-AD test in Europe and the United States.
RoundSeries A
Amount€5.4M
LeadClave Capital
Date2023-10-06
CityL'Hospitalet de Llobregat
SectorBiotech / Diagnostics
The company
Investors 6
CClave Capital
clave.capital
AAlzheimer's Drug Discovery Foundation (ADDF) Diagnostics Accelerator
EEIC Fund
eic.ec.europa.eu
L
Lavanda Ventures
SShip2B Ventures
www.ship2bventures.com
WWA4STEAM
wa4steam.com